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Objective: The e-BioMatrix is a post marketing multicenter registry with an objective to
evaluate the 2 year clinical safety and efficacy outcomes in patients treated with
BioMatrix - Biolimus A9 (BA9) drug eluting stents (DES).
Background: Drug-eluting stents still have late-stage disadvantages that might be attribut-
able to the permanent polymer. BioMatrix a new generation DES containing anti-
proliferative drug Biolimus A9 incorporating a biodegradable abluminal coating that
leaves a polymer-free stent after drug release enhancing strut coverage while preventing
neointimal hyperplasia.search Department, India. Tel.: þ91 0 7387777465 (mobile).
ndia.com (H. Rangnekar).
2013, Cardiological Society of India. All rights reserved.
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 5 9 3e5 9 9594Methods: This interim analysis consists of a total of 1189 patients with 1418 lesions treated
with BioMatrix stent who entered this multicenter registry in India. We analyzed the
incidence of major adverse cardiac events (MACE) and stent thrombosis (ST) at 1, 6, and 12
months with an extended follow-up of 2 years. Recommended antiplatelet regimen
included clopidogrel and aspirin for 12 months.
Results: The mean age was 57.6  10.9 years, 81.8% were males, comorbidity index was
1.20  1.33, 68% presented with acute coronary syndrome, 49% had hypertension and 40.8%
had diabetes mellitus. One-year clinical follow-up was completed in 987 patients at the
time of interim analysis. The incidence of MACE is 0.45 for 1544 person-year follow-up.
There were only 03 cases of ST (01 late ST) reported during this time.
Conclusion: This registry demonstrates excellent one-year clinical safety and efficacy of
BioMatrix stents. The 1-year result shows that BioMatrix stent may be a suitable alternative
as compared to contemporary DESs which are currently available in the market for simple
as well complex disease.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Introduction than its analogs) rapidly absorbed in tissues, and is able toEra of Percutaneous Coronary Intervention (PCI) started with
plain old balloon angioplasty (POBA) and progressed to bare
metal stent (BMS) and then to drug-eluting stent (DES). In DES,
polymer was used in addition to the drug, so that it could hold
the drug on the stent platform and could facilitate controlled
drug release. Thus, drug andpolymer becamehallmark of DES.
The first generation drugs utilizedwith DESs for prevention
of restenosis were sirolimus1e5 and paclitaxel.6,7 Large cohort
studies8,9 have reported rates of ST between 0.7% and 1.7% in
the first year and<0.6% per year depending on the type of DES
implanted, and the population studied. Several recent studies
have shown that limus derivatives are superior to paclitaxel
delivered from a durable polymer platform.10e12 Stent throm-
bosis remains the main safety concern and long-term
complication associated with the use of both BMS and DES.
Even though the initial clinical trials that led to the approval of
DESs included low- to moderate-risk, patients with de novo
lesions in native coronary arteries,13e16 majority of patients
treated in daily clinical practice fall outside the approved in-
dications of DES.17,18 This is especially relevant with respect to
stent thrombosis (ST), as the rates are higher in real world
patients than in those frompivotal trials.19,20 Currentpolymer-
basedDESsallow for controlled releaseof therapeutic agentsat
the site of injury. The second generation DES, have shown to
have lower adverse event rates and target lesion revasculari-
zation than BMSs attesting to the efficacy and safety of these
devices.21,22 Then, came the era of biodegradable polymerDES,
which was intended to lower late ST associated with persis-
tenceofdurablepolymersafter completionofdrugrelease.The
efficacy of biodegradable polymer coated DES has been proved
in terms of clinical and angiographic outcomes.17,23,24 Couple
of other randomized trials have also supported these estab-
lished results.25,26
BioMatrix-Biolimus A9 eluting stent is a new generation
DES incorporating a biodegradable polymer containing the
antiproliferative drug Biolimus A9 that is only coated on the
abluminal side. The proprietary is a semi-synthetic Sirolimus
analog and shares a similar adverse event profilewhen used at
equivalent dose levels. It is highly lipophilic, (10 times morereversibly inhibit growth factor-stimulated cell proliferation.
Current data suggests that Biolimus A9, on amolecular level,
forms a complex with the cytoplasmic proteins that inhibit
the cell cycle between the G0 and G1 phase. The result is an
interruption of the cascade governing cell metabolism,
growth, and proliferation. The safety and efficacy of BioMatrix
has been established in LEADERS trial,27 which showed BA9
with biodegradable polymer had 80% relative risk reduction of
very late stent thrombosis (1e4 years) when compared to first
generation durable polymer DES. BioMatrix stent was shown
to have a higher degree of functional re-endothelialization
due to improved vasomotion as compared to SES at 6e9
months post stent implantation.28 More complete strut
coverage was observed in an optical coherence tomography
substudy29 of the LEADERS trial patients allocated to BESs at 9
months when compared with SESs suggesting complete
endothelialization, which may have impact on clinical
outcome and, in particular, on the risk of late stent throm-
bosis. The potential clinical advantage of BES is expected to
emerge at acute and mainly during longer-term follow-up
once the polymer had completely metabolized. The pivotal
DES studies were largely done with strict inclusion criteria,
which limit wider applicability of their results to real world
setting. Post marketing surveillance registry studies play an
important role in extrapolating the outcomes of these studies
to day-to-day clinical practice.
This registry studywas initiated in India with aim to gather
the clinical outcomes of patients for a period of 2 years who
received BioMatrix stents during PCI. The interim analysis
from this multicenter post market surveillance registry in-
cludes the initial report of 1-year follow-up in terms of inci-
dence of MACE (major adverse cardiac events) and
consequences of stent thrombosis (ST).2. Methodology
This is a prospective observational study of patients who
underwent implantation of BioMatrix stents conducted at 18
interventional cardiology sites in India between December
Table 1 e Age group distribution.
Age group %
25e35 1.7
35e45 9.3
45e55 26.6
55e65 36.3
65e75 19.8
75e85 5.3
85e95 0.9
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was device oriented major adverse cardiac events (MACE)
defined as composite of cardiac death, myocardial infarction
[MI], or target vessel revascularization [TVR] within the study
population at 12 months follow-up. The secondary endpoints
were stent thrombosis (ST); MACE; any cause mortality, MI, or
any clinically driven TVR; death and MI and total revascular-
ization rate at 1, 6, 12, and 24 months.
The inclusion criteria for the study were e patients eligible
for PCI with lesions suitable for stent implantation with age
18 years, presence of 1 coronary artery stenoses in a native
coronary artery or saphenous bypass graft or radial vein graft
from 2.25 to 4.0 mm in diameter that can be covered with one
or multiple stents with no limitation to the number of treated
lesions, number of treated vessels or lesion length. Those
patients who received additional stent other than BioMatrix
were excluded. The Ethics Committee approval was sought
and consent for participation was obtained from each willing
and eligible patient before or after PCI who underwent im-
plantation of Biolimus A9 eluting stent according to stan-
dard procedure.
Implantation of BioMatrix stent in each target lesion during
the index procedure was mandatory. The appropriate length
and diameter of the stents to be implanted ensuring complete
coverage of the lesion were chosen by visual estimate. At least
2 mm overlap was achieved if more than one stent was
implanted. Treatment of multiple target vessels (within the
same procedure) and staged procedures which occur within
90 days of the initial implant procedure were allowed. Every
vessel in which a BioMatrix stent was implanted within 90
days of the initial implant procedure was considered a target
vessel. All postoperativemedicalmanagement, including dual
antiplatelet therapy, was prescribed according to usual local
practice at the discretion of the cardiologist. The data
collected by the registry include demographic information,
cardiovascular history, comorbidity, lesion and procedure
characteristics, antiplatelet regimen, and on events if any.
Patients were followed at 1, 6, 12 and 24 months by on-site
visit with study physicians or telephone communication. The
adverse event assessment was done in hospital. Interven-
tional cardiologists selected to participate as investigators in
this registry were qualified and/or board certified. The study
data were monitored on-site by the study monitoring group
for consistency with source data and to ensure compliance
with the protocol as well as Indian regulatory guidelines. This
PMS is notified to DCG(I) and is registered with clinical trial
registry of India with CRTI number: CTRI/2012/05/002657.
The Drug Eluting Coronary Stent System (BioMatrix DES)
is comprised of two key components: the stent (which in-
cludes Biolimus A9 incorporated into a polymer coating),
and the delivery catheter. A balloon expandable 316L stainless
steel stent with polymer coating containing Biolimus A9 is
pre-mounted onto a high pressure, semi-compliant rapid ex-
change balloon delivery system available in six and nine cell
models. The delivery catheter has two radiopaque markers,
which fluoroscopically mark the ends of the stent to facilitate
proper stent placement. The nominal dosage of Biolimus A9
for the BioMatrix stent ranges from 133 to 451 mg depending
on stent length. The biodegradable polymer is polylactic acid
(PLA), which has been widely used in a variety of medicalapplications, including orthopedic and dental devices and
implants. The biodegradable polymer is applied to the stent’s
abluminal surface, which is metabolized within 6e9 months.
BA9 appears to have higher degree of functional re-
endotheliazation and better arterial healing.30
An Independent Clinical Events Committee adjudicated all
MACE and other Serious Adverse Event (SAE) developing in the
patient population. The Committee arbitrated all MACE, other
SAE and ST by a systematic review of the data collection forms
and by review of the source documents, electrocardiograms,
and angiograms, when necessary.
All statistical analyses were performed with SPSS (Version
16.0). Standard descriptive statistics were used for baseline,
lesion, and procedural characteristics and for clinical results
for all patients. Continuous variables were presented as
mean  SD and range, and categorical variables were pre-
sented as numbers and percentages. Descriptive data of the
patient population and serious adverse events were compiled
as per protocol specified time intervals. As this is an interim
analysis and follow-up is in progress, we have different
quantum of follow-up done for patients. Calculations in the
paper are based on person-year calculations. Definition of
Person-Year: A measurement combining the number of per-
sons and their time contribution in a study. The two year
clinical outcome data will include stratified analyses accord-
ing to the presence or absence of DM, ACS, acute ST-elevation
myocardial infarction, left anterior descending artery, multi-
vessel disease, reference vessel diameter, LVEF, small-vessel
disease, and long-lesions (Table 1).3. Results
The e-BioMatrix study database registry interim data anal-
ysis includes 1189 patients recruited between December
2008 and February 2012 with 1418 lesions. The age group
distribution is described in Table 1. Patients’ baseline de-
mographics are summarized in Table 2. Mean age was
57.6  10.9 years (range 25e88), comorbidity index was
1.20  1.33, angiographic LVEF (%) was 50.2  11.9% (range
15e95) of which 278 (24.69%) had angiographic LVEF 40%.
Patients included were compliant with the eligibility criteria
specified in the protocol. Study comprised the entire clinical
spectrum of coronary artery disease, more than half (68%) of
the patients had an acute coronary syndrome (ACS), a high
proportion of patients (40.8%) had diabetes, 49% had
Table 2 e Baseline characteristics.
BES (n ¼ 1189) % BES (n ¼ 1189)
Diabetes mellitus- 40.8 Male 81.8%
Current smoker 17.0 Female 18.2%
Renal insufficiency at screening 1.3 Average age (yrs) 57.6
Hypercholesterolemia 14.9 Average LVEF 50.2
Hypertension 49.0 LVEF  40 24.6%
Family history of CAD 9.2 Total number of lesions treated 1418
Stroke 1.2 Lesion per patient 1.19
Congestive heart failure 3.5 Total number of stents 1520
Previous myocardial infarction 7.0 Stent per patient 1.27
Previous CABG 2.3 Long length (28 mm) 24.5%
Previous PCI(s) 4.7 Small vessel (2.75 mm) 46%
Peripheral vascular disease 0.9 Lesion treated previously 0.8%
Acute coronary syndromes 68.3 Total occlusion 15.87%
Asymptomatic 6.9
Silent ischemia only 9.5 Single vessel (SVD) 83.9%
Stable angina 15.3 Multi vessel (MVD) 16.1%
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were current smokers. A total of 1520 Biolimus eluting stents
were implanted during the index procedure. Almost one half
of the patients, 46% had lesions that were 2.75 mm in
diameter and one fourth, 24.5% patients had long length
lesions (stent length ranged between 8 and 28 mm). Most of
the lesions were located in the left anterior descending ar-
tery (51.5%). Multiple vessel intervention was performed in
16.1% of patients. On average, 1.27 stents were used to treat
1.19 lesions per patient. Total percentage of lesion segment
is described in Table 3.
The interim analysis includes clinical follow-up data
equivalent to 1544 person-year follow-up. Clinical/Telephonic
follow-up was complete in 99.8% of the patients at day 30, in
99.4% at sixmonths, and in 97.9% at 12months. Table 4 shows
the number of patients taking dual antiplatelet therapy
(DAPT) at 1, 6, and 12 months.
Non-hierarchy approach was used for counting of MACE.
The cumulative rates of major adverse cardiac clinical events
and overall ST classification are presented in Tables 5 and 6.
The incidence rate for MACE in 1544 person (patient) years
was 0.45. There were 4 cardiac deaths, 1 case of myocardial
infarction and 2 cases of TVR reported during the 1-year
follow-up period. The incidence rate of overall stent throm-
bosis was 0.2 in 1544 person (patient) years. Of 3 patients who
developed ST, one each presented with acute onset within
24 h, subacute onset within 1 month and late onset within
1 year.Table 3 e Total percentage of lesion segments.
Lesion segment %
LAD 51.5
LCX 23.9
RCA 23.1
Left main 1.1
Bypass graft stenting 0.24. Discussion
Our post marketing surveillance registry was designed to
support the long-term safety and efficacy of the BioMatrix
stent for treatment of coronary artery lesions in real world
clinical practice. This registry characterizes one of the largest
prospective single arm studies in India. A significant per-
centage of the patients had diabetes and more than half pre-
sented with ACS. The interim analysis findings of 1-year
clinical follow-up exhibit very low rates of MACE (cardiac
death, TVR and MI) and stent thrombosis.
The first generation DES, e-Cypher Registry31 of 15,157
patients treated with SES Cypher stent (J&J, Cordis Corpora-
tion, Bridgewater NJ) reported a MACE rate (all death, MI, and
TLR) of 1.36% at 30 days and 5.8% and cumulative ST rate was
0.87% at 1 year. In the BerneRotterdam registry, the rate of
definite ST was 3.6% at 4 years with paclitaxel-eluting
stents vs. 2.7% with SES.13 Subsequently, the WISDOM
registry32 of 778 patients treated with the Express2 PES re-
ported a 12 month MACE rate (death, MI, and TLR) of 5.2% and
a protocol-defined ST rate of 0.6%. The combined ARRIVE
1 and ARRIVE 233 registry population of 7492 patients who
underwent deployment of the TAXUS Express2 PES had a
higher 1-year MACE rate (cardiac death, MI, TVR) of 9.5% and
ARC-defined definite and probable ST rate of 1.8% than simple
use patients in the pivotal trials. The SORT OUT II randomizedTable 4 e Patient taking DAPT.
DAPT Visit description
30 days
follow-up
(n ¼ 1169)
6-months
follow-up
(n ¼ 1126)
12 months
follow-up
(n ¼ 987)
Patient taking
DAPT
99.3% 99.6% 99.3%
Non-hierarchy approach was used for counting of MACE.
Table 5 e Major adverse cardiac events.
*MACE (major adverse
cardiac event)
Numbers MACE Incidence rate
per 100
person-year
Cardiac death 4 7 0.45
Myocardial infarction 1
TVR 2
*Major adverse cardiac events (MACE) within the study population,
defined as composite of cardiac death, myocardial infarction (Q-
wave and non-Q-wave), or justified target vessel revascularization
at 12 months.
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reported no significant differences in clinical outcomes with
MACE rate of 9.3% (SES) vs. 11.2% (PES) and stent thrombosis
rate of 2.5% (SES) vs. 2.9% (PES).34
The second generation ZES and EES stents have been
compared in randomized trials with the SES35 and PES.36 The
X-SEARCH study showed subacute and late definite ST rates of
0.3% and 0%, respectively, at 6-month follow-up.37 The
COMPARE trial (EES and PES) at 1 year reported rates of sub-
acute and late ST as 0.1% and 0.4%, respectively.4 The reported
rate of cardiac death was 1.1%, overall MI was 3.5% and cu-
mulative rate of definite and probable ST was 0.66% in SPIRIT
V Clinical Evaluation of the XIENCE V EES.38 The results of EES
post marketing registry39 have also demonstrated low rate of
ARC-defined definite and probable ST of 0.84% and composite
rate of cardiac death and ARC-defined myocardial infarction
of 6.5% in the overall population. Considering the results from
these studies, the lower ST through 1 year seen in e-BioMatrix
registry is quite supportive of an indication of long-term
benefit of BA9 eluting stent.
Recently, CREATE post marketing surveillance registry of
biodegradable SES has demonstrated cumulative rate ofMACE
to be 7.4% and the rate of stent thrombosis to be 2.4% at five
years40 which were very less compared with other registries
like Sirius, Taxus-IV SR and Endeavor II.
The safety and efficacy of BioMatrix been established in
large randomized controlled trial called LEADERS trial29,
which showed BA9 with biodegradable polymer had 80%
relative risk reduction of very late stent thrombosis (1e4
years) when compared to first generation durable polymer
DES. Clinical trial with BA9 eluting stents conducted in the
recent decade has also established its high efficacy in reducing
late lumen loss post PCI.41
The interim results from our e-BioMatrix registry
contribute significantly towards the analysis of the incidence
and clinical impact of MACE and ST receiving BioMatrix stentsTable 6 e Definite and probable stent thrombosis.
Stent
thrombosis
Acute Subacute Late Very
late
Total Incidence
rate per 100
person-year
Definite 1 1 1 0 3 0.2
Probable 0 0 0 0 0 3
Total: 3in real world setting. In our registry, patientswho received BES
stents, the incidence of MACE (Cardiac Death, MI, TVR) and ST
at 12 months of clinical follow-up were significantly lower
(0.45 and 0.2 per 100 person-year). There was only one re-
ported case of late ST. These results are quite lower than the
recent real world registry trial42 of ZES and EES with reported
of 0.9% and 1.2% and XIENCE India single arm43 trial, which
reported cumulative ST of 0.5% at 1-year follow-up. Our 1-year
clinical outcome data showed clinical benefit of biodegradable
polymer BioMatrix stents, which was primarily attributable to
reduced risk of very late definite ST. This analysis includes
2-year follow-up of 37% of enrolled patients, in which there
was not a single case of very late stent thrombosis. Thus,
BioMatrix DES appears to have excellent clinical outcome
applicable to real world setting. The initial findings from this
registry also suggests that favorable results from earlier ran-
domized trials of BioMatrix stent can be seen in daily clinical
practice involving patients with significant comorbidities and
complex disease.5. Study limitations
Since patients treated with other than Biolimus stents
during the index procedure was an exclusion criterion, no
information was collected on other DES, which might
have contributed to some degree of selection bias. Secondly,
the study design was single arm with no control arm for
direct comparison. However, these limitations are part of any
post marketing surveillance registry.6. Conclusion
In conclusion, the 1-year incidence of MACE in this cohort of
patients treated with BioMatrix stents was significantly lower
as compared to previously published data. The incidence of
stent thrombosis was also very low as compared to similar
other registries. Thus, this interim 1-year follow-up results
show that BioMatrix stent could be a suitable alternative even
in high risk patients to contemporary DES which are currently
available in themarket. Highlights like advanced stent design,
highly lipophilic Biolimus A9 drug (which is 10 times more
lipophilic than its analogs), biodegradable polymer (PLA) and
their application on the abluminal side of the stent could be
responsible for better results of BioMatrix BES. The final
analysis will include results of two years.Conflicts of interest
Tushar Mhetre and Hrishikesh Rangnekar are working for
Biosensors International, India.
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